Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
173 hedge funds and large institutions have $2.28B invested in Juno Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 52 increasing their positions, 50 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
80% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 20
47% more capital invested
Capital invested by funds: $1.55B → $2.28B (+$731M)
10% more funds holding
Funds holding: 157 → 173 (+16)
4% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 50
31% less call options, than puts
Call options by funds: $31.1M | Put options by funds: $45.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$54.8M |
| 2 |
O
OrbiMed
New York
|
+$22.6M |
| 3 |
Jennison Associates
New York
|
+$18.7M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$16.3M |
| 5 |
Morgan Stanley
New York
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$11.7M |
| 2 |
BCM
Biomark Capital Management
Greenwich,
Connecticut
|
-$7.51M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$6.21M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.5M |
| 5 |
PP
Peconic Partners
New York
|
-$3.33M |
JUNO Hedge Fund Activity: Q2 2017 in Review
173 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q2 2017, worth a combined $2.28B — up 47% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new JUNO positions and 20 closed out — a net gain of 16 holders — while 52 added to existing stakes and 50 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $54.8M. The largest seller was HealthCor Management, exiting entirely with an estimated $11.7M sold.
- 173 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q2 2017, up from 157 in Q1 2017.
- Funds reported $2.28B of Juno Therapeutics, Inc. stock for Q2 2017, up 47% quarter-over-quarter.
- 36 funds opened new Juno Therapeutics, Inc. positions in Q2 2017 and 20 closed out, a net change of +16 holders.
- The largest Juno Therapeutics, Inc. buyer in Q2 2017 was Redmile Group, an estimated $54.8M added.
- The largest Juno Therapeutics, Inc. seller in Q2 2017 was HealthCor Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2017.